Jahnz-Rózyk, K <br/><br/>
Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis.  [electronic resource] 

 -  Allergy  Jul 2003 
 - 595-601 p.  digital 
<br/><br/> Publication Type: Comparative Study; Evaluation Study; Journal Article 
<br/><br/><label>ISSN: </label>0105-4538 
<br/><br/><label>Standard No.: </label>10.1034/j.1398-9995.2003.00083.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Inhalation<br/>Adult<br/>Allergens--adverse effects<br/>Anti-Allergic Agents--therapeutic use<br/>Betula--adverse effects<br/>Biomarkers--blood<br/>Chemokines, CC--blood<br/>Conjunctivitis, Allergic--blood<br/>Desensitization, Immunologic<br/>Drug Therapy, Combination<br/>Edible Grain--adverse effects<br/>Female<br/>Histamine H1 Antagonists, Non-Sedating--therapeutic use<br/>Humans<br/>Hypersensitivity, Immediate--blood<br/>Immunoglobulin E--blood<br/>Loratadine--therapeutic use<br/>Male<br/>Poaceae--adverse effects<br/>Poland--epidemiology<br/>Pollen--adverse effects<br/>Rhinitis, Allergic, Seasonal--blood<br/>Statistics as Topic<br/>Treatment Outcome